Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb booster trial of a SARS-CoV-2 variant mRNA chimera S protein vaccine after 3-dose inactivated COVID-19 vaccination
ChiCTR2200065281Phase 3Not yet recruiting
- Sponsor
- Yunnan Provincial Center for Disease Control and Prevention
- Start
- Nov 2022
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of LVRNA010, adenovirus type 5 vector vaccine and ZF2001 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Yunnan Provincial Center for Disease Control and Prevention. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
LVRNA010adenovirus type 5 vector vaccineZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200065281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065281.